Research ArticleArticle
Uptake and Clinical Utility of Multibiomarker Disease Activity Testing in the United States
Jeffrey R. Curtis, Fenglong Xie, Shuo Yang, Maria I. Danila, Justin K. Owensby and Lang Chen
The Journal of Rheumatology November 2018, jrheum.180071; DOI: https://doi.org/10.3899/jrheum.180071
Jeffrey R. Curtis
From the Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA. Dr. Curtis receives support from the US National Institutes of Health (NIH; P60 AR064172) and the Patient-Centered Outcome Research Institute. Dr. Curtis also had research grants and/or consulting fees from Amgen, BMS, Corrona, Janssen, Myriad Genetics, Pfizer, and UCB. Dr. Danila receives support from the NIH (P60 AR064172) and has had research grants from Pfizer. This study had additional support from Myriad Genetics. The manuscript content and decision to submit for publication was solely the purview of the authors and not conditional on external approval. J.R. Curtis, MD, MS, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; F. Xie, PhD, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; S. Yang, MS, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; M.I. Danila, MD, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; J.K. Owensby, PharmD, PhD, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; L. Chen, PhD, University of Alabama at Birmingham. Address correspondence to Dr. J.R. Curtis, 510 20th St. South, UAB FOT 802, Birmingham, Alabama 35294, USA. E-mail: jrcurtis@uabmc.edu. Accepted for publication July 26, 2018.
Fenglong Xie
From the Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA. Dr. Curtis receives support from the US National Institutes of Health (NIH; P60 AR064172) and the Patient-Centered Outcome Research Institute. Dr. Curtis also had research grants and/or consulting fees from Amgen, BMS, Corrona, Janssen, Myriad Genetics, Pfizer, and UCB. Dr. Danila receives support from the NIH (P60 AR064172) and has had research grants from Pfizer. This study had additional support from Myriad Genetics. The manuscript content and decision to submit for publication was solely the purview of the authors and not conditional on external approval. J.R. Curtis, MD, MS, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; F. Xie, PhD, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; S. Yang, MS, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; M.I. Danila, MD, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; J.K. Owensby, PharmD, PhD, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; L. Chen, PhD, University of Alabama at Birmingham. Address correspondence to Dr. J.R. Curtis, 510 20th St. South, UAB FOT 802, Birmingham, Alabama 35294, USA. E-mail: jrcurtis@uabmc.edu. Accepted for publication July 26, 2018.
Shuo Yang
From the Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA. Dr. Curtis receives support from the US National Institutes of Health (NIH; P60 AR064172) and the Patient-Centered Outcome Research Institute. Dr. Curtis also had research grants and/or consulting fees from Amgen, BMS, Corrona, Janssen, Myriad Genetics, Pfizer, and UCB. Dr. Danila receives support from the NIH (P60 AR064172) and has had research grants from Pfizer. This study had additional support from Myriad Genetics. The manuscript content and decision to submit for publication was solely the purview of the authors and not conditional on external approval. J.R. Curtis, MD, MS, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; F. Xie, PhD, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; S. Yang, MS, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; M.I. Danila, MD, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; J.K. Owensby, PharmD, PhD, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; L. Chen, PhD, University of Alabama at Birmingham. Address correspondence to Dr. J.R. Curtis, 510 20th St. South, UAB FOT 802, Birmingham, Alabama 35294, USA. E-mail: jrcurtis@uabmc.edu. Accepted for publication July 26, 2018.
Maria I. Danila
From the Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA. Dr. Curtis receives support from the US National Institutes of Health (NIH; P60 AR064172) and the Patient-Centered Outcome Research Institute. Dr. Curtis also had research grants and/or consulting fees from Amgen, BMS, Corrona, Janssen, Myriad Genetics, Pfizer, and UCB. Dr. Danila receives support from the NIH (P60 AR064172) and has had research grants from Pfizer. This study had additional support from Myriad Genetics. The manuscript content and decision to submit for publication was solely the purview of the authors and not conditional on external approval. J.R. Curtis, MD, MS, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; F. Xie, PhD, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; S. Yang, MS, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; M.I. Danila, MD, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; J.K. Owensby, PharmD, PhD, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; L. Chen, PhD, University of Alabama at Birmingham. Address correspondence to Dr. J.R. Curtis, 510 20th St. South, UAB FOT 802, Birmingham, Alabama 35294, USA. E-mail: jrcurtis@uabmc.edu. Accepted for publication July 26, 2018.
Justin K. Owensby
From the Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA. Dr. Curtis receives support from the US National Institutes of Health (NIH; P60 AR064172) and the Patient-Centered Outcome Research Institute. Dr. Curtis also had research grants and/or consulting fees from Amgen, BMS, Corrona, Janssen, Myriad Genetics, Pfizer, and UCB. Dr. Danila receives support from the NIH (P60 AR064172) and has had research grants from Pfizer. This study had additional support from Myriad Genetics. The manuscript content and decision to submit for publication was solely the purview of the authors and not conditional on external approval. J.R. Curtis, MD, MS, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; F. Xie, PhD, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; S. Yang, MS, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; M.I. Danila, MD, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; J.K. Owensby, PharmD, PhD, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; L. Chen, PhD, University of Alabama at Birmingham. Address correspondence to Dr. J.R. Curtis, 510 20th St. South, UAB FOT 802, Birmingham, Alabama 35294, USA. E-mail: jrcurtis@uabmc.edu. Accepted for publication July 26, 2018.
Lang Chen
From the Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA. Dr. Curtis receives support from the US National Institutes of Health (NIH; P60 AR064172) and the Patient-Centered Outcome Research Institute. Dr. Curtis also had research grants and/or consulting fees from Amgen, BMS, Corrona, Janssen, Myriad Genetics, Pfizer, and UCB. Dr. Danila receives support from the NIH (P60 AR064172) and has had research grants from Pfizer. This study had additional support from Myriad Genetics. The manuscript content and decision to submit for publication was solely the purview of the authors and not conditional on external approval. J.R. Curtis, MD, MS, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; F. Xie, PhD, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; S. Yang, MS, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; M.I. Danila, MD, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; J.K. Owensby, PharmD, PhD, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; L. Chen, PhD, University of Alabama at Birmingham. Address correspondence to Dr. J.R. Curtis, 510 20th St. South, UAB FOT 802, Birmingham, Alabama 35294, USA. E-mail: jrcurtis@uabmc.edu. Accepted for publication July 26, 2018.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Uptake and Clinical Utility of Multibiomarker Disease Activity Testing in the United States
Jeffrey R. Curtis, Fenglong Xie, Shuo Yang, Maria I. Danila, Justin K. Owensby, Lang Chen
The Journal of Rheumatology Nov 2018, jrheum.180071; DOI: 10.3899/jrheum.180071